MarketPulse

pharmaceutical growth

5 articles
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

CVS and AbbVie Emerge as Healthcare Recovery Plays Amid Market Downturn

CVS and AbbVie emerge as recovery opportunities post-market pullback, leveraging diversified operations and immunology momentum respectively, with strong dividend backing investor confidence.
ABBVCVSdividend stockshealthcare stocks
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Eli Lilly Edges Vertex as Superior Growth Pick Amid GLP-1 Boom

Eli Lilly ($LLY) outpaces Vertex ($VERX) as superior growth stock pick with Zepbound dominance in booming weight-loss market and stronger financials at comparable valuations.
LLYVRTXcystic fibrosispharmaceutical growth
The Motley FoolThe Motley Fool··Adria Cimino

Eli Lilly's Market Dominance vs. Viking's Promise: Weight Loss Drug Showdown

Eli Lilly dominates weight loss drugs with 60% U.S. market share and triple-digit growth, while Viking Therapeutics advances competitive VK2735. Lilly's 8% YTD decline and 28x forward earnings may offer value.
LLYNVOVKTXclinical trialsmarket share
The Motley FoolThe Motley Fool··Adria Cimino

Two Biotech Leaders Poised for Growth in 2026: REGN and VERX

Regeneron and Vertex Pharmaceuticals emerge as compelling 2026 biotech investments, with REGN valued at 17x and VERX at 24x forward earnings, offering growth and stability respectively.
VRTXREGNpharmaceutical growthinvestment recommendation
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Healthcare Sector Poised for Growth as CVS and Vertex Eye Strategic Milestones

CVS and Vertex poised for growth through 2026 via operational improvements and expanded product pipelines. Both companies expected to deliver significant shareholder value.
CVSVRTXbiotechhealthcare stocks